DYNAMICS OF SST2 AND NT-PROBNP IN PATIENTS WITH ARTERIAL HYPERTENSION AND TYPE 2 DIABETES MELLITUS BASED ON COMBINED THERAPY WITH EPLERENONE AND TRIMETASIDINE ADDITION

被引:0
|
作者
Bilovol, O. M. [1 ]
Kniazkova, I. I. [1 ]
Kirienko, O. M. [1 ]
Kuzminova, N. V. [2 ]
Sushetska, A. S. [1 ]
Starenkiy, V. P. [1 ]
Abramova, L. P. [1 ]
机构
[1] Kharkiv Natl Med Univ, Kharkiv, Ukraine
[2] Natl Pirogov Mem Med Univ, Vinnytsya, Ukraine
来源
WORLD OF MEDICINE AND BIOLOGY | 2023年 / 83卷 / 01期
关键词
soluble growth-stimulatingreceptor expressed by gene 2; N-terminal fragment of brain natriuretic propeptide; diastolic function; arterial hypertension; type 2 diabetes mellitus; eplerenone; trimetazidine; SOCIETY;
D O I
10.26724/2079-8334-2023-1-83-21-25
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
The purpose of our study was to investigate the effect of complex therapy with the addition of eplerenone and trimetazidine on the state of left ventricular diastolic function, as well as levels of soluble growth-stimulatingreceptor expressed by gene 2 and N-terminal fragment of brain natriuretic propeptide in patients with arterial hypertension with type 2 diabetes mellitus. After registration baseline data were recorded, 42 patients (group 1) were prescribed baseline therapy and 38 patients (group 2) were prescribed eplerenone 25-50 mg once daily and trimetazidine 80 mg once daily in addition to antihypertensive therapy for 3 months. The control group consisted of 20 practically healthy individuals. After the treatment, a significant decrease in the level of soluble growth-stimulatingreceptor expressed by gene 2 in the blood of patients in both groups was found, but in group 2 this indicator did not differ from the control group, while in group 1 it remained significantly higher than in healthy individuals. At the same time, the level of N-terminal fragment of brain natriuretic propeptide significantly decreased by 1.3 times and 1.6 times in groups 1 and 2, respectively, but remained significantly higher than in the control group. A significant decrease E/e`mean was determined in both groups of patients, but in group 2 by 8.9 % less than in group 2 and a decrease in the geometric parameters of the left atrium, more pronounced in group 2. Thus, the addition of eplerenone and trimetazidine to the complex therapy of patients with arterial hypertension and type 2 diabetes mellitus during 3 months improved diastolic function, and also had a positive effect on the biomarker of myocardial stress and fibrosis soluble growth-stimulatingreceptor expressed by gene 2 level and myocardial dysfunction N-terminal fragment of brain natriuretic propeptide concentration in serum
引用
收藏
页码:21 / 25
页数:5
相关论文
共 50 条
  • [21] Multimarker testing with NT-proBNP and sST2 in predicting of cardiovascular complications in patients with ST-segment elevation myocardial infarction
    Barnett, O. Olga
    Kyyak, Y.
    Halkevych, M.
    Labinska, O.
    EUROPEAN JOURNAL OF HEART FAILURE, 2022, 24 : 93 - 93
  • [22] The Implication of NT-proBNP in the Assessment of the Clinical Phenotype of Patients with Type 2 Diabetes Mellitus, Without Established Cardiovascular Disease
    Gastouniotis, Ioannis
    Fragoulis, Christos
    Antonopoulos, Alexis
    Kouroutzoglou, Alexandrina
    Noutsou, Marina
    Thanopoulou, Anastasia
    Chrysohoou, Christina
    Tsioufis, Konstantinos P.
    BIOMEDICINES, 2024, 12 (12)
  • [23] Relationship between sST2 and NT-proBNP levels and postoperative atrial fibrillation in patients having non-cardiac surgery
    Somuncu, Mustafa U.
    Gudul, Naile E.
    Kokturk, Ugur
    Koksal, Bengu G.
    Tatar, Fatih P.
    Avci, Ahmet
    MINERVA CARDIOLOGY AND ANGIOLOGY, 2024,
  • [24] Therapy of hypertension in patients with type 2 diabetes mellitus
    Hess, K.
    DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 2012, 137 (48) : 2489 - 2492
  • [25] Looking into the Kinetics of NT-proBNP and sST2 Changes in Patients with Heart Failure Treated with Sacubitril/Valsartan: A Hint to Different Therapeutic Pathways
    Mapelli, Massimo
    Mattavelli, Irene
    Salvioni, Elisabetta
    Bonomi, Alice
    Capra, Nicolo
    Palermo, Pietro
    Banfi, Cristina
    Paolillo, Stefania
    Biondi, Maria Luisa
    Agostoni, Piergiuseppe
    DRUGS IN R&D, 2023, 23 (04) : 397 - 402
  • [26] To support the use of NT-proBNP to better detect heart failure in patients with type 2 diabetes
    Lapi, Francesco
    Marconi, Ettore
    Medea, Gerardo
    Parretti, Damiano
    Piccinni, Carlo
    Maggioni, Aldo Pietro
    Cricelli, Claudio
    ENDOCRINE, 2023, 82 (01) : 42 - 46
  • [27] Metformin treatment may be associated with decreased levels of NT-proBNP in patients with type 2 diabetes
    Rosiak, M.
    Postula, M.
    Kaplon-Cieslicka, A.
    Trzepla, E.
    Czlonkowski, A.
    Filipiak, K. J.
    Opolski, G.
    ADVANCES IN MEDICAL SCIENCES, 2013, 58 (02): : 362 - 368
  • [28] Elevated plasma levels of Nt-proBNP in patients with type 2 diabetes without cardiovascular disease
    Magnusson, M
    Melander, O
    Israelsson, B
    Grubb, A
    Groop, L
    Jovinge, S
    DIABETES CARE, 2004, 27 (08) : 1929 - 1935
  • [29] Looking into the Kinetics of NT-proBNP and sST2 Changes in Patients with Heart Failure Treated with Sacubitril/Valsartan: A Hint to Different Therapeutic Pathways
    Massimo Mapelli
    Irene Mattavelli
    Elisabetta Salvioni
    Alice Bonomi
    Nicolò Capra
    Pietro Palermo
    Cristina Banfi
    Stefania Paolillo
    Maria Luisa Biondi
    Piergiuseppe Agostoni
    Drugs in R&D, 2023, 23 : 397 - 402
  • [30] To support the use of NT-proBNP to better detect heart failure in patients with type 2 diabetes
    Francesco Lapi
    Ettore Marconi
    Gerardo Medea
    Damiano Parretti
    Carlo Piccinni
    Aldo Pietro Maggioni
    Claudio Cricelli
    Endocrine, 2023, 82 : 42 - 46